In a nutshell, this investigation suggested whether HAMP could be considered a new biomarker for diagnosing early-stage HCC and used to predict the sensitivity and prognosis of PD-1 immunotherapy, in addition to orienting the development of new drugs. This evidence concerns the gene HAMP and hepatocellular carcinoma.